MX2018003235A - Composiciones de flavonoide y metodos de uso. - Google Patents

Composiciones de flavonoide y metodos de uso.

Info

Publication number
MX2018003235A
MX2018003235A MX2018003235A MX2018003235A MX2018003235A MX 2018003235 A MX2018003235 A MX 2018003235A MX 2018003235 A MX2018003235 A MX 2018003235A MX 2018003235 A MX2018003235 A MX 2018003235A MX 2018003235 A MX2018003235 A MX 2018003235A
Authority
MX
Mexico
Prior art keywords
methods
improving
flavonoid
quercetin
flavonoid compositions
Prior art date
Application number
MX2018003235A
Other languages
English (en)
Inventor
richards Kurt
Original Assignee
Reoxcyn LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reoxcyn LLC filed Critical Reoxcyn LLC
Publication of MX2018003235A publication Critical patent/MX2018003235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)

Abstract

Se describen composiciones de flavonoide que contienen el flavonoide quercetina y/o derivados de quercetina. Las composiciones de flavonoide son formuladas para mejorar la biodisponibilidad de la quercetina. También se proporcionan en la presente métodos para mejorar el desempeño atlético, mejorar la salud cardiovascular y ayudar a la respuesta inmune, y métodos para mejorar el desempeño atlético, mejorar la salud ósea, prevenir la fatiga, reducir el tiempo de recuperación después del ejercicio, contrarrestar la tensión oxidativa y/o reforzar la energía.
MX2018003235A 2015-09-23 2016-09-22 Composiciones de flavonoide y metodos de uso. MX2018003235A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222667P 2015-09-23 2015-09-23
PCT/US2016/053141 WO2017053583A1 (en) 2015-09-23 2016-09-22 Flavonoid compositions and methods of use

Publications (1)

Publication Number Publication Date
MX2018003235A true MX2018003235A (es) 2019-02-07

Family

ID=58276476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003235A MX2018003235A (es) 2015-09-23 2016-09-22 Composiciones de flavonoide y metodos de uso.

Country Status (13)

Country Link
US (1) US9839624B2 (es)
EP (1) EP3352774A4 (es)
JP (3) JP6471268B2 (es)
KR (2) KR20180075504A (es)
CN (1) CN108135952A (es)
AU (1) AU2016326523B2 (es)
CA (1) CA2999763C (es)
HK (1) HK1256608A1 (es)
MX (1) MX2018003235A (es)
NZ (1) NZ741022A (es)
RU (1) RU2721425C2 (es)
WO (1) WO2017053583A1 (es)
ZA (1) ZA201801511B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US10441621B2 (en) * 2015-09-23 2019-10-15 Reoxcyn, Llc Flavonoid compositions and methods of use
JP6709847B2 (ja) 2015-09-30 2020-06-17 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 非食物アレルギーを管理するためのペットフード組成物
WO2019043846A1 (ja) * 2017-08-30 2019-03-07 大塚製薬株式会社 ケンペロール類縁体含有組成物
CN108938618B (zh) * 2018-06-25 2022-04-22 中国科学院动物研究所 延缓人间充质干细胞衰老的化合物及其应用
CN108774203A (zh) * 2018-06-25 2018-11-09 北京未蓝时代科技有限公司 一种延缓哺乳动物细胞和机体衰老的化合物及其应用
US11304968B2 (en) 2018-11-16 2022-04-19 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide
US10639294B2 (en) 2018-10-02 2020-05-05 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide metabolite
KR102070701B1 (ko) * 2019-05-02 2020-01-29 (주)오르나 빌베리 착즙액, 씨벅톤 착즙액 및 링곤베리 착즙액를 포함하는 항산화 조성물
WO2021023857A1 (en) * 2019-08-08 2021-02-11 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives
IT201900023997A1 (it) * 2019-12-13 2021-06-13 Mario Paolo Donnaloja Integratore alimentare per la regolazione del metabolismo
IT202000014686A1 (it) * 2020-06-18 2021-12-18 Enervit S P A Integratore alimentare per migliorare il metabolismo energetico e ridurre lo stress ossidativo cellulare
KR102184823B1 (ko) * 2020-07-15 2020-12-01 주식회사 오르나 블랙커런트, 링곤베리 및 씨벅손 추출물을 포함하는 항산화 조성물
RU2762824C1 (ru) * 2020-11-17 2021-12-23 Диковский Александр Владимирович Комбинация для снижения окислительного стресса в организме и поддержания функций печени
CN113712982B (zh) * 2021-09-13 2022-12-06 广东金骏康生物技术有限公司 一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用
CN114948929A (zh) * 2022-04-08 2022-08-30 上海市中医医院 一种槲皮素的用途
CN115887543B (zh) * 2023-01-29 2023-06-02 中国农业大学 刺梨多酚在制备预防或治疗肠道疾病的药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821536B2 (en) * 2002-11-22 2004-11-23 Quercegen Holdings Llc Antioxidative compositions
US20040126461A1 (en) * 2002-10-23 2004-07-01 Lines Thomas Christian Composition for enhancing physical performance
US7569239B2 (en) * 2002-11-22 2009-08-04 The Frs Company Antioxidative compositions
US20050238731A1 (en) * 2003-12-29 2005-10-27 Stephen Holt Composition and method for treating the effects of diseases and maladies of the upper digestive tract
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
US20060172012A1 (en) * 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
US20090018186A1 (en) * 2006-09-06 2009-01-15 The Coca-Cola Company Stable beverage products comprising polyunsaturated fatty acid emulsions
CN101632655B (zh) * 2009-08-04 2011-12-07 南京大渊美容保健有限公司 延缓衰老的白藜芦醇和生物类黄酮营养组合物
TW201201712A (en) * 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products
CN101856121B (zh) * 2010-05-19 2012-05-23 北京联合大学生物化学工程学院 一种咀嚼片及其制备方法
CA2808313C (en) * 2010-08-13 2021-04-13 Rhode Island Board Of Governors For Higher Education Liposomes comprising ph low insertion peptide (phlip) polypeptides
US8752704B2 (en) * 2010-12-17 2014-06-17 The Procter & Gamble Company Blister cards promoting intuitive dosing
US20120183587A1 (en) * 2011-01-18 2012-07-19 Mitsunori Ono Flavonol compositions
US8846061B1 (en) * 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
PL2685994T3 (pl) * 2011-03-17 2016-05-31 Probiotical Spa Bakterie probiotyczne wykazujące aktywność przeciwutleniającą i ich zastosowanie
JP6000690B2 (ja) * 2012-06-28 2016-10-05 東芝メディカルシステムズ株式会社 在宅医療支援装置及び在宅医療支援システム
US20140322389A1 (en) * 2013-03-14 2014-10-30 Indra Prakash Beverages containing rare sugars
TW201532621A (zh) * 2013-04-22 2015-09-01 Neocutis Sa 抗氧化劑組成物及其使用方法

Also Published As

Publication number Publication date
JP2019089788A (ja) 2019-06-13
EP3352774A1 (en) 2018-08-01
RU2018107713A3 (es) 2019-10-23
RU2721425C2 (ru) 2020-05-19
JP6471268B2 (ja) 2019-02-13
ZA201801511B (en) 2019-09-25
JP2018530601A (ja) 2018-10-18
WO2017053583A1 (en) 2017-03-30
JP6936932B2 (ja) 2021-09-22
NZ741022A (en) 2019-07-26
CN108135952A (zh) 2018-06-08
KR102160428B1 (ko) 2020-09-29
KR20200035174A (ko) 2020-04-01
RU2018107713A (ru) 2019-10-23
AU2016326523A1 (en) 2018-05-10
HK1256608A1 (zh) 2019-09-27
US9839624B2 (en) 2017-12-12
AU2016326523B2 (en) 2019-04-04
CA2999763C (en) 2022-07-12
EP3352774A4 (en) 2019-04-03
JP7121056B2 (ja) 2022-08-17
KR20180075504A (ko) 2018-07-04
US20170079947A1 (en) 2017-03-23
CA2999763A1 (en) 2017-03-30
JP2020055879A (ja) 2020-04-09

Similar Documents

Publication Publication Date Title
MX2018003235A (es) Composiciones de flavonoide y metodos de uso.
EP3426061A4 (en) METHOD AND COMPOSITIONS FOR IMPROVING WEIGHT DECREASE AND CARDIOMETABOLIC HEALTH OVER DIET AND EXERCISE
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX2021006734A (es) Metodo para tratar el cancer.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
PH12015502167A1 (en) Methods of maintaining and improving muscle function
ZA202305280B (en) Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX2018002344A (es) Metodo para tratar el cancer.
MY182593A (en) Composition containing chitin and digestible proteins
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
BR112017004202A2 (pt) composições para intensificar respostas imunes e seus usos
PH12016501968A1 (en) Novel macrocyclic compounds
MX370628B (es) Composiciones y metodos para tratar las espinillas.
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
DK3242957T3 (da) Bakterieholdige sammensætninger og fremgangsmåder til anvendelse af samme til behandling og/eller forebyggelse af gastrointestinale, metaboliske og/eller andre sygdomme
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
EA033540B1 (ru) Композиция, включающая окру, для применения в уменьшении абсорбции пищевого жира
MX2021016114A (es) Formulaciones para estabilizar la humedad en alimentos musculares.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
TW201613569A (en) Composition consisting of kukoamine A and/or kukoamine B and method of using thereof
MX2018007737A (es) Suplementos masticables de fruta.
WO2016093613A3 (ko) 진피 추출물을 포함하는 이상 체중 감소 증상의 예방 또는 치료용 조성물
MX2017000740A (es) Composicion dietetica con actividad antidislipidemica.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: CASTEL INNOVATIONS, LLC